A consensus approach to the classification of pediatric pulmonary hypertensive vascular disease: Report from the PVRI pediatric taskforce, panama 2011

Pulmonary Circulation

Volumn 1, Issue 2, 2011, Pages 286-298

  Del Cerro, Maria Jesus ^a   Abman, Steven ^b   Diaz, Gabriel ^c   Freudenthal, Alexandra Heath ^d   Freudenthal, Franz ^d   Harikrishnan, S ^e   Haworth, Sheila G ^f   Ivy, Dunbar ^b   Lopes, Antonio A ^g   Usha Raj, J ^h   Sandoval, Julio ⁱ   Stenmark, Kurt ^b   Adatia, Ian ^j  

^a HOSPITAL INFANTIL LA PAZ   (Spain)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^d Kardiozentrum   (Bolivia)

^e SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY   (India)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^j UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

Pediatric patient; Pulmonary hypertension; Pulmonary hypertension in the newborn; Pulmonary vascular disease

Indexed keywords

EID: 84856385121     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.83456     Document Type: Article

References (165)

1. Rich S. Primary pulmonary hypertension: Executive summary from the world symposium-primary pulmonary hypertension 1998. Paper presented at: World Health Organisation, 1998; Evian.
2. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43 Suppl 12:5S-12.
3. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
4. Díaz G. Aspectos Generales; Definición Clasificación y Epidemiología. In: Díaz G, Sandoval J, Sola A, editors. Hipertensión Pulmonar en Niños. Bogotá: Editorial Médica Distribuna; 2011. p. 9-19.
5. van Albada ME, Berger RM. Pulmonary arterial hypertension in congenital cardiac disease--the need for refinement of the Evian-Venice classification. Cardiol Young 2008;18:10-7.
6. van Loon RL, Roofthooft MT, van Osch-Gevers M, Delhaas T, Strengers JL, Blom NA, et al. Clinical characterization of pediatric pulmonary hypertension: Complex presentation and diagnosis. J Pediatr 2009;155: 176-82.e1.
7. Schulze-Neick I, Beghetti M. Classifying pulmonary hypertension in the setting of the congenitally malformed heart--cleaning up a dog’s dinner. Cardiol Young 2008;18:22-5.
8. Barker DJ. The developmental origins of adult disease. J Am Coll Nutr 2004;23 Suppl 6:588S-95.
9. Reid LM. Lung growth in health and disease. Br J Dis Chest 1984;78: 113-34.
10. Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. Adv Exp Med Biol 2010;661:323-35.
11. Eulmesekian P, Cutz E, Parvez B, Bohn D, Adatia I. Alveolar capillary dysplasia: A six-year single center experience. J Perinat Med 2005;33: 347-52.
12. Rowe R, James L. The normal pulmonary arterial pressure during the first year of life. J Pediatr 1957;51:1-4.
13. Lock J, Einzig S, Moller J. Hemodynamic responses to exercise in normal children. Am J Cardiol 1978;41:1278-84.
14. Haworth SG. Pulmonary hypertension in childhood. Eur Respir J 1993;6:1037-43.
15. Hansen AR, Barnes CM, Folkman J, McElrath TF. Maternal preeclampsia predicts the development of bronchopulmonary dysplasia. J Pediatr 2010;156:532-6.
16. Maeno YV, Kamenir SA, Sinclair B, van der Velde ME, Smallhorn JF, Hornberger LK. Prenatal features of ductus arteriosus constriction and restrictive foramen ovale in d-transposition of the great arteries. Circulation 1999;99:1209-14.
17. Castillo M, Vade A, Lim-Dunham JE, Masuda E, Massarani-Wafai R. Pulmonary interstitial glycogenosis in the setting of lung growth abnormality: Radiographic and pathologic correlation. Pediatr Radiol 2010;40:1562-5.
18. Deutsch GH, Young LR, Deterding RR, Fan LL, Dell SD, Bean JA, et al. Diffuse lung disease in young children: Application of a novel classification scheme. Am J Respir Crit Care Med 2007;176:1120-8.
19. Chen S, Ursell PC, Adatia I, Hislop AA, Giannikopoulos P, Hornberger LK. Prenatal diagnosis of primary pulmonary hypoplasia in fraternal twins. Ultrasound Obstet Gynecol 2010;35:113-6.
20. Inwald D, Brown K, Gensini F, Malone M, Goldman A. Open lung biopsy in neonatal and paediatric patients referred for extracorporeal membrane oxygenation (ECMO). Thorax 2004;59:328-33.
21. Yu S, Shao L, Kilbride H, Zwick DL. Haploinsufficiencies of FOXF1 and FOXC2 genes associated with lethal alveolar capillary dysplasia and congenital heart disease. Am J Med Genet A 2010;152:1257-62.
22. Stankiewicz P, Sen P, Bhatt SS, Storer M, Xia Z, Bejjani BA, et al. Genomic and genic deletions of the FOX gene cluster on 16q24.1 and inactivating mutations of FOXF1 cause alveolar capillary dysplasia and other malformations. Am J Hum Genet 2009;84:780-91.
23. Shaw-Smith C. Genetic factors in esophageal atresia, tracheo-esophageal fistula and the VACTERL association: Roles for FOXF1 and the 16q24.1 FOX transcription factor gene cluster, and review of the literature. Eur J Med Genet 2010;53:6-13.
24. Vassal HB, Malone M, Petros AJ, Winter RM. Familial persistent pulmonary hypertension of the newborn resulting from misalignment of the pulmonary vessels (cogenital alveolar capillary dysplasia). J Med Genet 1998;35:58-60.
25. Han RN, Babaei S, Robb M, Lee T, Ridsdale R, Ackerley C, et al. Defective lung vascular development and fatal respiratory distress in endothelial NO synthase-deficient mice: A model of alveolar capillary dysplasia? Circ Res 2004;94:1115-23.
26. Kitagawa M, Hislop A, Boyden EA, Reid L. Lung hypoplasia in congenital diaphragmatic hernia: A quantitative study of airway, artery, and alveolar development. Br J Surg 1971;58:342-6.
27. Cooney TP, Thurlbeck WM. Pulmonary hypoplasia in Down’s syndrome. N Engl J Med 1982;307:1170-3.
28. Sherer DM, Davis JM, Woods JR Jr. Pulmonary hypoplasia: A review. Obstet Gynecol Surv 1990;45:792-803.
29. Askenazi SS, Perlman M. Pulmonary hypoplasia: Lung weight and radial alveolar count as criteria of diagnosis. Arch Dis Child 1979;54:614-8.
30. Murphy JD, Vawter GF, Reid LM. Pulmonary vascular disease in fatal meconium aspiration. J Pediatr 1984;104:758-62.
31. Geggel RL, Reid LM. The structural basis of PPHN. Clin Perinatol 1984;11:525-49.
32. Haworth SG, Reid L. Persistent fetal circulation: Newly recognized structural features. J Pediatr 1976;88:614-20.
33. Guillot L, Carre A, Szinnai G, Castanet M, Tron E, Jaubert F, et al. NKX2 1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in “Brain-Lung-Thyroid Syndrome.” Hum Mutat 2010;31:E1146-62.
34. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond) 2009;116:27-35.
35. Kinsella JP, Neish SR, Shaffer E, Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:819-20.
36. Kinsella JP, Abman SH. Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1995;126:853-64.
37. Abman SH, Chatfield BA, Hall SL, McMurtry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol 1990;259:H1921-7.
38. Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Dilleen M, Oakes M, et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009;155:841-7.e1.
39. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010;11 Suppl 2:S79-84.
40. Thebaud B, Tibboel D. Pulmonary hypertension associated with congenital diaphragmatic hernia. Cardiol Young 2009;19 Suppl 1:49-53.
41. Kinsella JP, Ivy DD, Abman SH. Pulmonary vasodilator therapy in congenital diaphragmatic hernia: Acute, late, and chronic pulmonary hypertension. Semin Perinatol 2005;29:123-8.
42. Chang AC, Macrae D. Neonates with congenital cardiac defects and pulmonary hypertension. Cardiol Young 2009;19 Suppl 1:4-7.
43. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: A pilot randomized blinded study. Pediatrics 2006;117:1077-83.
44. Peñaloza D, Sime F, Ruiz L. Pulmonary hemodynamics in children living at high altitudes. High Alt Med Biol 2008;9:199-207.
45. Díaz G, Márquez A. Hipertensión Pulmonar en Niños a Moderada Altura en Hipertensión Pulmonar en Niños. In: Díaz G, Sandoval J, Sola A, editors. Hipertensión Pulmonar en Niños. Bogotá: Editorial Médica Distribuna; 2011. p. 266-84.
46. Gamboa R, Marticorena E. Pulmonary arterial pressure in newborn infants in high altitude. Arch Inst Biol Andina 1971;4:55-66.
47. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: The UK Pulmonary Hypertension Service for Children 2001-2006. Heart 2009;95:312-7.
48. Adatia I, Kothari SS, Feinstein JA. Pulmonary hypertension associated with congenital heart disease: Pulmonary vascular disease: The global perspective. Chest 2010;137 Suppl 6:52S-61.
49. Fasnacht MS, Tolsa JF, Beghetti M. The Swiss registry for pulmonary arterial hypertension: The paediatric experience. Swiss Med Wkly 2007;137:510-3.
50. Adatia I, Mullen M, Kulik TJ. Pulmonary venous hypertension or pulmonary hypertension due to left heart disease. Prog Pediatr Cardiol 2009;27:35-42.
51. Kulik T, Mullen M, Adatia I. Pulmonary arterial hypertension associated with congenital heart disease. Prog Pediatr Cardiol 2009;27:25-33.
52. Roberts KE, McElroy JJ, Wong WP, Yen E, Widlitz A, Barst RJ, et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004;24:371-4.
53. Cordina R, Celermajer D. Late-onset pulmonary arterial hypertension after a successful atrial or arterial switch procedure for transposition of the great arteries. Pediatr Cardiol 2010;31:238-41.
54. Kumar A, Taylor G, Sandor G, Patterson M. Pulmonary vascular disease in neonates with transposition of the great arteries and intact ventricular septum. Br Heart J 1993;69:442-5.
55. Sreeram N, Petros A, Peart I, Arnold R. Progressive pulmonary hypertension after the arterial switch procedure. Am J Cardiol 1994;73:620-1.
56. Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prevert S, Rizzoli G, et al. Eisenmenger syndrome factors relating to deterioration and death. Eur Heart J 1998;19:1845-55.
57. van Loon RL, Hoendermis ES, Duffels MG, Vonk-Noordegraaf A, Mulder BJ, Hillege HL, et al. Long-term effect of bosentan in adults versus children with pulmonary arterial hypertension associated with systemic-to-pulmonary shunt: Does the beneficial effect persist? Am Heart J 2007;154:776-82.
58. Bograd AJ, Mital S, Schwarzenberger JC, Mosca RS, Quaegebeur JM, Addonizio LJ, et al. Twenty-year experience with heart transplantation for infants and children with restrictive cardiomyopathy: 1986-2006. Am J Transplant 2008;8:201-7.
59. Daftari B, Alejos JC, Perens G. Initial experience with sildenafil, bosentan, and nitric oxide for pediatric cardiomyopathy patients with elevated pulmonary vascular resistance before and after orthotopic heart transplantation. J Transplant 2010;2010:656984.
60. de Leval MR. The Fontan circulation: A challenge to William Harvey? Nat Clin Pract Cardiovasc Med 2005;2:202-8.
61. de Leval MR, Deanfield JE. Four decades of Fontan palliation. Nat Rev Cardiol 2010;7:520-7.
62. Khambadkone S, Li J, de Leval MR, Cullen S, Deanfield JE, Redington AN. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation 2003;107:3204-8.
63. La Gerche A, Gewillig M. What limits cardiac performance during exercise in normal subjects and in healthy fontan patients? Int J Pediatr 2010;2010.pii:791291.
64. Giardini A, Balducci A, Specchia S, Gargiulo G, Bonvicini M, Picchio FM. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J 2008;29:1681-7.
65. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: Twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 2005;111:3274-80.
66. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant 2005;24:1174-6.
67. Uzun O, Wong JK, Bhole V, Stumper O. Resolution of protein-losing enteropathy and normalization of mesenteric Doppler flow with sildenafil after Fontan. Ann Thorac Surg 2006;82:e39-40.
68. Ovaert C, Thijs D, Dewolf D, Ottenkamp J, Dessy H, Moons P, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young 2009;19:331-9.
69. Heath A, Stewart K, Mendes J, Ramirez M, Freudenthal F. Does High altitude protect against irreversible pulmonary hypertension? PVRI Rev 2010;2:131-3.
70. Sime F, Banchero N, Peñaloza D, Gamboa R, Cruz J, Marticorena E. Pulmonary hypertension in children born and living at high altitudes. Am J Cardiol 1963;11:143-9.
71. Penaloza D, Arias-Stella J, Sime F, Recavarren S, Marticorena E. The Heart and pulmonary circulation in children at high altitudes: physiological, anatomical, and clinical observations. Pediatrics 1964;34:568-82.
72. Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: Healthy highlanders and chronic mountain sickness. Circulation 2007;115:1132-46.
73. Cutz E, Chiasson D. Chronic lung disease after premature birth. N Engl J Med 2008;358:743-5; author reply 745-6.
74. Mourani PM, Mullen M, Abman SH. Pulmonary hypertension in bronchopulmonary dysplasia. Prog Pediatr Cardiol 2009;27:43-8.
75. Stenmark KR, Abman SH. Lung vascular development: Implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 2005;67:623-61.
76. Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol 2003;8:73-81.
77. Bancalari E, Claure N. Definitions and diagnostic criteria for bronchopulmonary dysplasia. Semin Perinatol 2006;30:164-70.
78. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007;357:1946-55.
79. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: Clinical features and outcomes in the surfactant era. Pediatrics 2007;120:1260-9.
80. Krishnan U, Krishnan S, Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008;29:1082-6.
81. Drossner DM, Kim DW, Maher KO, Mahle WT. Pulmonary vein stenosis: Prematurity and associated conditions. Pediatrics 2008;122:e656-61.
82. Seale AN, Webber SA, Uemura H, Partridge J, Roughton M, Ho SY, et al. Pulmonary vein stenosis: The UK, Ireland and Sweden collaborative study. Heart 2009;95:1944-9.
83. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84.
84. Moledina S, Hislop AA, Foster H, Schulze-Neick I, Haworth SG. Childhood idiopathic pulmonary arterial hypertension: A national cohort study. Heart 2010;96:1401-6.
85. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jais X, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 2010;181:851-61.
86. Fraisse A, Jais X, Schleich JM, di Filippo S, Maragnes P, Beghetti M, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch Cardiovasc Dis 2010;103:66-74.
87. Mathew R, Huang J, Katta US, Krishnan U, Sandoval C, Gewitz MH. Immunosuppressant-induced endothelial damage and pulmonary arterial hypertension. J Pediatr Hematol Oncol 2011;33:55-8.
88. Yildizdas D, Erdem S, Kucukosmanoglu O, Yilmaz M, Yuksel B. Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Adv Ther 2008;25:515-9.
89. Silvani P, Camporesi A, Mandelli A, Wolfler A, Salvo I. A case of severe diazoxide toxicity. Paediatr Anaesth 2004;14:607-9.
90. Karaman MG, Atalay F, Tufan AE, Erdogan A. Pulmonary arterial hypertension in an adolescent treated with methylphenidate. J Child Adolesc Psychopharmacol 2010;20:229-31.
91. Lewman LV. Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets. Hum Pathol 1972;3:67-70.
92. Barst RJ, Abenhaim L. Fatal pulmonary arterial hypertension associated with phenylpropanolamine exposure. Heart 2004;90:e42.
93. Patel MS, Taylor GP, Bharya S, Al-Sanna’a N, Adatia I, Chitayat D, et al. Abnormal pericyte recruitment as a cause for pulmonary hypertension in Adams-Oliver syndrome. Am J Med Genet 2004;129A:294-9.
94. Bergman JE, Blake KD, Bakker MK, du Marchie Sarvaas GJ, Free RH, van Ravenswaaij-Arts CM. Death in CHARGE syndrome after the neonatal period. Clin Genet 2010;77:232-40.
95. Baskar S, Kulkarni ML, Kulkarni AM, Vittalrao S, Kulkarni PM. Adams-Oliver syndrome: Additions to the clinical features and possible role of BMP pathway. Am J Med Genet A 2009;149:1678-84.
96. Hess OM, Steurer J, Goebel NH, Kuhlmann U, Krayenbuhl HP. Goldenhar syndrome. Schweiz Med Wochenschr 1979;109:19-23.
97. Argueta-Morales IR, Meador LC, Nykanen DG, DeCampli WM. Infantile form of scimitar syndrome with contralateral pulmonary vein stenosis. Pediatr Cardiol 2010;31:550-2.
98. Salerno T, Guccione P, Malena S, Cutrera R. Horseshoe lung associated with unique left pulmonary vein: An unreported association. Pediatr Cardiol 2010;31:905-7.
99. Cua CL, Blankenship A, North AL, Hayes J, Nelin LD. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 2007;28:250-4.
100. Levine OR, Harris RC, Blanc WA, Mellins RB. Progressive pulmonary hypertension in children with portal hypertension. J Pediatr 1973;83:964-72.
101. Simeoni S, Puccetti A, Chilosi M, Tinazzi E, Prati D, Corrocher R, et al. Type 1 neurofibromatosis complicated by pulmonary artery hypertension: A case report. J Med Invest 2007;54:354-8.
102. Stewart DR, Cogan JD, Kramer MR, Miller WT Jr, Christiansen LE, Pauciulo MW, et al. Is pulmonary arterial hypertension in neurofibromatosis type 1 secondary to a plexogenic arteriopathy? Chest 2007;132:798-808.
103. Engel PJ, Baughman RP, Menon SG, Kereiakes DJ, Taylor L, Scott M. Pulmonary hypertension in neurofibromatosis. Am J Cardiol 2007;99: 1177-8.
104. Aoki Y, Kodama M, Mezaki T, Ogawa R, Sato M, Okabe M, et al. von Recklinghausen disease complicated by pulmonary hypertension. Chest 2001;119:1606-8.
105. Banka S, Newman WG, Ozgul RK, Dursun A. Mutations in the G6PC3 gene cause Dursun syndrome. Am J Med Genet A 2010;152:2609-11.
106. Scurr I, Wilson L, Lees M, Robertson S, Kirk E, Turner A, et al. Cantu syndrome: Report of nine new cases and expansion of the clinical phenotype. Am J Med Genet A 2011;155:508-18.
107. Suzuki K, Yamaki S, Mimori S, Murakami Y, Mori K, Takahashi Y, et al. Pulmonary vascular disease in Down’s syndrome with complete atrioventricular septal defect. Am J Cardiol 2000;86:434-7.
108. Matsumura Y, Ban N, Inagaki N. Aberrant catalytic cycle and impaired lipid transport into intracellular vesicles in ABCA3 mutants associated with nonfatal pediatric interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2008;295:L698-707.
109. Park SK, Amos L, Rao A, Quasney MW, Matsumura Y, Inagaki N, et al. Identification and characterization of a novel ABCA3 mutation. Physiol Genomics 2010;40:94-9.
110. Babyn PS, Gahunia HK, Massicotte P. Pulmonary thromboembolism in children. Pediatr Radiol 2005;35:258-74.
111. Tavil B, Kuskonmaz B, Kiper N, Cetin M, Gumruk F, Gurgey A. Pulmonary thromboembolism in childhood: A single-center experience from Turkey. Heart Lung 2009;38:56-65.
112. Brandstetter Y, Weinhouse E, Splaingard ML, Tang TT. Cor pulmonale as a complication of methylmalonic acidemia and homocystinuria (Cbl-C type). Am J Med Genet 1990;36:167-71.
113. Staser JA, Alam T, Applegate K. Calcified pulmonary thromboembolism in a child with sickle cell disease: Value of multidetector CT in patients with acute chest syndrome. Pediatr Radiol 2006;36:561-3.
114. Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009;33:325-31.
115. Branch GL, Castle RF. Thromboembolic complications in primary endocardial fibroelastosis. J Pediatr 1966;69:250-8.
116. Johnson JN, Driscoll DJ, McGregor CG. Pulmonary thromboendarterectomy in adolescents and young adults. Pediatr Pulmonol 2010;45:614-8.
117. Lambert V, Durand P, Devictor D, Planche C, Serraf A. Unilateral right pulmonary thromboendarterectomy for chronic embolism: A successful procedure in an infant. J Thorac Cardiovasc Surg 1999;118:953-4; discussion 57.
118. Groves BM, Droma T, Sutton JR, McCullough RG, McCullough RE, Zhuang J, et al. Minimal hypoxic pulmonary hypertension in normal Tibetans at 3,658 m. J Appl Physiol 1993;74:312-8.
119. Fagan KA, Weil JV. Potential genetic contributions to control of the pulmonary circulation and ventilation at high altitude. High Alt Med Biol 2001;2:165-71.
120. Yaron M, Niermeyer S, Lindgren KN, Honigman B, Strain JD, Cairns CB. Physiologic response to moderate altitude exposure among infants and young children. High Alt Med Biol 2003;4:53-9.
121. Maggiorini M, Leon-Velarde F. High-altitude pulmonary hypertension: A pathophysiological entity to different diseases. Eur Respir J 2003;22: 1019-25.
122. Fasules JW, Wiggins JW, Wolfe RR. Increased lung vasoreactivity in children from Leadville, Colorado, after recovery from high-altitude pulmonary edema. Circulation 1985;72:957-62.
123. Gabry AL, Ledoux X, Mozziconacci M, Martin C. High-altitude pulmonary edema at moderate altitude (< 2,400 m; 7,870 feet): A series of 52 patients. Chest 2003;123:49-53.
124. Das BB, Wolfe RR, Chan KC, Larsen GL, Reeves JT, Ivy D. High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch Pediatr Adolesc Med 2004;158:1170-6.
125. Durmowicz AG. Pulmonary edema in 6 children with Down syndrome during travel to moderate altitudes. Pediatrics 2001;108:443-7.
126. Sui GJ, Liu YH, Cheng XS, Anand IS, Harris E, Harris P, et al. Subacute infantile mountain sickness. J Pathol 1988;155:161-70.
127. Ivy DD, Feinstein JA, Humpl T, Rosenzweig EB. Non-congenital heart disease associated pediatric pulmonary arterial hypertension. Prog Pediatr Cardiol 2009;27:13-23.
128. Cataltepe S, van Marter LJ, Kozakewich H, Wessel DL, Lee PJ, Levy HL. Pulmonary hypertension associated with nonketotic hyperglycinaemia. J Inherit Metab Dis 2000;23:137-44.
129. del Toro M, Arranz JA, Macaya A, Riudor E, Raspall M, Moreno A, et al. Progressive vacuolating glycine leukoencephalopathy with pulmonary hypertension. Ann Neurol 2006;60:148-52.
130. Leal GN, de Paula AC, Leone C, Kim CA. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 2010;20:254-61.
131. Ueno M, Murakami T, Takeda A, Kubota M. Efficacy of oral sildenafil in a beraprost-treated patient with severe pulmonary hypertension secondary to type I glycogen storage disease. Circ J 2009;73:1965-8.
132. Hino T, Hayashida A, Okahashi N, Wada N, Watanabe N, Obase K, et al. Portopulmonary hypertension associated with congenital absence of the portal vein treated with bosentan. Intern Med 2009;48:597-600.
133. Ohno T, Muneuchi J, Ihara K, Yuge T, Kanaya Y, Yamaki S, et al. Pulmonary hypertension in patients with congenital portosystemic venous shunt: A previously unrecognized association. Pediatrics 2008;121:e892-9.
134. Iqbal CW, Krowka MJ, Pham TH, Freese DK, El Youssef M, Ishitani MB. Liver transplantation for pulmonary vascular complications of pediatric end-stage liver disease. J Pediatr Surg 2008;43:1813-20.
135. Newman B, Feinstein JA, Cohen RA, Feingold B, Kreutzer J, Patel H, et al. Congenital extrahepatic portosystemic shunt associated with heterotaxy and polysplenia. Pediatr Radiol 2010;40:1222-30.
136. Alghamdi MH, Steinraths M, Panagiotopoulos C, Potts JE, Sandor GG. Primary pulmonary arterial hypertension and autoimmune polyendocrine syndrome in a pediatric patient. Pediatr Cardiol 2010;31:872-4.
137. Xing Y, Song HM, Wu XY, He YY, Wei M. Clinical analysis of pulmonary arterial hypertension secondary to connective tissue disease in children. Zhonghua Er Ke Za Zhi 2008;46:822-6.
138. Haworth SG, Hislop A, Reid L. Editorial: Progressive pulmonary hypertension in children with portal hypertension. J Pediatr 1974;84:783-5.
139. Silver MM, Bohn D, Shawn DH, Shuckett B, Eich G, Rabinovitch M. Association of pulmonary hypertension with congenital portal hypertension in a child. J Pediatr 1992;120:321-9.
140. Naeye RL. “Primary” pulmonary hypertension with coexisting portal hypertension. A retrospective study of six cases. Circulation 1960;22: 376-84.
141. Saunders JB, Constable TJ, Heath D, Smith P, Paton A. Pulmonary hypertension complicating portal vein thrombosis. Thorax 1979;34:281-3.
142. Bower JS, Dantzker DR, Naylor B. Idiopathic pulmonary hypertension associated with nodular pulmonary infiltrates and portal venous thrombosis. Chest 1980;78:111-3.
143. Cohen MD, Rubin LJ, Taylor WE, Cuthbert JA. Primary pulmonary hypertension: An unusual case associated with extrahepatic portal hypertension. Hepatology 1983;3:588-92.
144. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987;10:1233-8.
145. Yutani C, Imakita M, Ishibashi-Ueda H, Okubo S, Naito M, Kunieda T. Nodular regenerative hyperplasia of the liver associated with primary pulmonary hypertension. Hum Pathol 1988;19:726-31.
146. Wanless IR, Albrecht S, Bilbao J, Frei JV, Heathcote EJ, Roberts EA, et al. Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: A new syndrome. Mod Pathol 1989;2:456-62.
147. Padeh S, Laxer RM, Silver MM, Silverman ED. Primary pulmonaryy hypertension in a patient with systemic-onset juvenile arthritis. Arthritis Rheum 1991;34:1575-9.
148. Connor P, Veys P, Amrolia P, Haworth S, Ashworth M, Moledina S. Pulmonary hypertension in children with Evans syndrome. Pediatr Hematol Oncol 2008;25:93-8.
149. Nagai H, Yasuma K, Katsuki T, Shimakura A, Usuda K, Nakamura Y, et al. Primary antiphospholipid syndrome and pulmonary hypertension with prolonged survival. A case report. Angiology 1997;48:183-7.
150. Espinosa G, Cervera R, Font J, Asherson RA. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002;61:195-8.
151. Sharma S, Kirpalani AL, Kulkarni A. Severe pulmonary hypertension in a young patient with end-stage renal disease on chronic hemodialysis. Ann Pediatr Cardiol 2010;3:184-6.
152. Yigla M, Nakhoul F, Sabag A, Tov N, Gorevich B, Abassi Z, et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003;123:1577-82.
153. Unal A, Sipahioglu M, Oguz F, Kaya M, Kucuk H, Tokgoz B, et al. Pulmonary hypertension in peritoneal dialysis patients: Prevalence and risk factors. Perit Dial Int 2009;29:191-8.
154. Amin M, Fawzy A, Hamid MA, Elhendy A. Pulmonary hypertension in patients with chronic renal failure: Role of parathyroid hormone and pulmonary artery calcifications. Chest 2003;124:2093-7.
155. Havlucu Y, Kursat S, Ekmekci C, Celik P, Serter S, Bayturan O, et al. Pulmonary hypertension in patients with chronic renal failure. Respiration 2007;74:503-10.
156. Adatia I. Pulmonary veno-occlusive disease. In: Freedom RM, Yoo SJ, Mikailian H, Williams WG, editors. The natural and modified history of congenital heart disease. New York: Futura; 2004. p. 513.
157. Kobayashi D, Cook, A, Williams D. Pulmonary hypertension secondary to partial pulmonary venous obstruction in a child with Cantú syndrome. Pediatr Radiol 2010;45:727-9.
158. Gewillig M, Brown SC, De Catte L, Debeer A, Eyskens B, Cossey V, et al. Premature foetal closure of the arterial duct: Clinical presentations and outcome. Eur Heart J 2009;30:1530-6.
159. Van Marter LJ, Leviton A, Allred EN, Pagano M, Sullivan KF, Cohen A, et al. Persistent pulmonary artery hypertension of the newborn and smoking and aspirin and nonsteroidal anti inflammatory drug consumption during pregnancy. Pediatrics 1996;97:658-63.
160. Siu KL, Lee WH. Maternal diclofenac sodium ingestion and severe neonatal pulmonary hypertension. J Paediatr Child Health 2004;40:152-3.
161. Schiessl B, Schneider KT, Zimmerman A, Kainer F, Friese K, Oberhoffer R. Prenatal constriction of the fetal ductus arteriosus-related to maternal pain medication? Z Geburtshilfe Neonatol 2005;209:65-8.
162. Alano MA, Ngougmna E, Ostrea EM Jr, Konduri GG. Analysis of nonsteroidal anti-inflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics 2001;107:519-23.
163. Zender M, Klinge J, Kruger C, Singer H, Scharf J. Severe pulmonary hypertension in a neonate caused by premature closure of the ductus arteriosus following maternal treatment with diclofenac: A case report. J Perinat Med 1998;26:231-4.
164. Mas C, Menahem S. Premature in utero closure of the ductus arteriosus following maternal ingestion of sodium diclofenac. Aust N Z J Obstet Gynaecol 1999;39:106-7.
165. Talati AJ, Salim MA, Korones SB. Persistent pulmonary hypertension after maternal naproxen ingestion in a term newborn: A case report. Am J Perinatol 2000;17:69-71.